Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the reporting period ending November 6, 2002. The document serves as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on changes in directors' interests and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction involving the Glaxo Wellcome Employee Trust ("the Trust"). On November 4, 2002, Abacus (GW) Trustees Limited sold 8,116 Ordinary Shares of the Company at a price of £12.05 per share. The Company was advised of this transaction on November 5, 2002.
Management Commentary and Risks
Management commentary is limited to the disclosure of the Trust transaction. The Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline Services Unlimited and its subsidiaries are potential beneficiaries. Director John Coombe is noted as having an interest in the shares held in the Trust in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations are detailed in this filing.
Key Facts for Investor Verification
- Director John Coombe holds an interest in the Glaxo Wellcome Employee Trust, which sold 8,116 shares on November 4, 2002.
- The sale price of the shares was £12.05 per share.
- This filing contains no financial performance metrics or operational guidance.